| 1 |
31810127 | The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. | 2020 Jan |
2 |
| 2 |
32864162 | Pharmacogenomics of COVID-19 therapies. | 2020 |
1 |
| 3 |
26952879 | Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. | 2016 Apr |
1 |
| 4 |
25661337 | Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. | 2015 Feb |
3 |
| 5 |
25661339 | ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. | 2015 Feb |
1 |
| 6 |
26071337 | Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. | 2015 Jul |
1 |
| 7 |
24957263 | Ribavirin uptake into human hepatocyte HHL5 cells is enhanced by interferon-α via up-regulation of the human concentrative nucleoside transporter (hCNT2). | 2014 Sep 2 |
3 |
| 8 |
23195617 | Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. | 2013 Apr |
2 |
| 9 |
19369574 | Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. | 2009 Jun |
2 |
| 10 |
17140564 | Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. | 2007 Feb 14 |
2 |
| 11 |
17700367 | Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. | 2007 Sep |
1 |